Free Trial

Northwest Biotherapeutics (OTCMKTS:NWBO) Stock Price Crosses Below 200 Day Moving Average - Here's Why

Northwest Biotherapeutics logo with Medical background

Shares of Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO - Get Free Report) crossed below its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $0.27 and traded as low as $0.25. Northwest Biotherapeutics shares last traded at $0.26, with a volume of 942,000 shares changing hands.

Northwest Biotherapeutics Stock Performance

The firm's 50-day moving average is $0.29 and its 200 day moving average is $0.27. The stock has a market cap of $375.99 million, a PE ratio of -3.69 and a beta of -1.09.

Northwest Biotherapeutics (OTCMKTS:NWBO - Get Free Report) last announced its quarterly earnings data on Thursday, May 15th. The biotechnology company reported ($0.01) EPS for the quarter. The business had revenue of $0.38 million for the quarter.

Northwest Biotherapeutics Company Profile

(Get Free Report)

Northwest Biotherapeutics, Inc, a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer.

Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Northwest Biotherapeutics Right Now?

Before you consider Northwest Biotherapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Northwest Biotherapeutics wasn't on the list.

While Northwest Biotherapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

The Next Palantir? AI-Defense Stock Set for Explosive Growth
2 Chip Stocks Are Soaring—But One Could Break Out This Summer
Congress Bought This Stock at the Bottom—Will You Miss It?

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines